热门资讯> 正文
2025-10-02 00:40
Aspire Biopharma Holdings shares are trading higher after the company announced a milestone roadmap targeting H2 2025 FDA Submission for Sublingual Asprin and 2026 milestones for Needle-Free Semaglutide and more-rapid ED medication.